1
|
Li X, Tong H, Xu B, Deng Y, Li Y, Huang J, Mao Y, Liu M, Zhang P, Guo S. A sensitive and high-throughput LC-ESI-MS/MS method to detect budesonide in human plasma: application to an evaluation of pharmacokinetics of budesonide intranasal formulations with and without charcoal-block in healthy volunteers. Drug Dev Ind Pharm 2021; 47:329-336. [PMID: 33523774 DOI: 10.1080/03639045.2021.1879842] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Budesonide is one of the intranasal corticosteroids, referred as first-line therapy for allergic rhinitis. Its determination is a challenging task due to its extremely low plasma levels, which limits the progress in the investigation of pharmacokinetics and quality control of preparations. In this study, a sensitive and high-throughput method to determine budesonide in human plasma using budesonide-d8 as the internal standard was developed and validated. A small volume of plasma sample (0.2 mL) was diluted with 0.2 mL water, followed by a solid-phase extraction using Cleanert PEP-2 products. Extracted samples were analyzed by liquid chromatography coupled to electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). Chromatographic separation of analytes was performed on an InertSustain AQ-C18 HP column (3 µm, 2.1 × 50 mm) under the reversed-phase condition with gradient elution. With the assay, linear calibration curves were obtained over the concentration range of 10-1200 pg/mL for budesonide, with considerable extraction recoveries (84.7-89.4%), and negligible matrix effects (<4.1). Moreover, the newly developed method was successfully applied to the evaluation of pharmacokinetics of two budesonide intranasal formulations with and without charcoal block in healthy volunteers.
Collapse
Affiliation(s)
- Xin Li
- Department of Pharmacy, The Third Hospital of Changsha, Changsha, China
| | - Huan Tong
- Department of Pharmacy, The Third Hospital of Changsha, Changsha, China
| | - Bing Xu
- Department of Pharmacy, The Third Hospital of Changsha, Changsha, China
| | - Yang Deng
- Department of Pharmacy, The Third Hospital of Changsha, Changsha, China
| | - Yuan Li
- Department of Pharmacy, The Third Hospital of Changsha, Changsha, China
| | - Junchen Huang
- Department of Pharmacy, The Third Hospital of Changsha, Changsha, China
| | - Yong Mao
- Chengdu Brilliant Pharmaceutical Co., Ltd, Chengdu, China
| | - Mengqin Liu
- Suzhou Guochen Biotechnology Co., Ltd, Suzhou, China
| | - Ping Zhang
- Department of Pharmacy, The Third Hospital of Changsha, Changsha, China
| | - Siwei Guo
- Department of Pharmacy, The Third Hospital of Changsha, Changsha, China
| |
Collapse
|
2
|
King K, Li P, Pietrasiewicz A, Goldstein S. Perspectives on updates, clarifications and controversies in chromatographic assay guidance for bioanalytical method validation from major regulatory agencies and organizations. Biomed Chromatogr 2020; 35:e5030. [PMID: 33201529 DOI: 10.1002/bmc.5030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Revised: 11/10/2020] [Accepted: 11/12/2020] [Indexed: 11/10/2022]
Abstract
Bioanalysis, a key supporting function for generating data for pre-clinical and clinical studies in drug development, is under the regulation of local agencies as well as global organizations to ensure the data integrity and quality in submission. As major regulatory agencies and organizations, the US Food and Drug Administration, the European Medicines Agency and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use have been updating their industry guidance for bioanalytical method validation, to keep up with the development new modalities, technologies and regulations. This article summarizes the recent updates and any clarifications and controversies triggered by those updates. Perspectives and recommendations are given based on our own experience as well as commonly accepted practice in the bioanalytical community.
Collapse
Affiliation(s)
- Kris King
- Department of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney St, Cambridge, MA, 02142, USA
| | - Pei Li
- Department of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney St, Cambridge, MA, 02142, USA
| | - Alicia Pietrasiewicz
- Department of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney St, Cambridge, MA, 02142, USA
| | - Stanley Goldstein
- Department of Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney St, Cambridge, MA, 02142, USA
| |
Collapse
|
3
|
Homšek A, Marković B, Bogavac-Stanojević N, Vladimirov S, Karljiković-Rajić K. Method Transfer Evaluation for Digital Derivative Spectrophotometry Through its Resolution Parameter Comparison of Different Computer Programs. APPLIED SPECTROSCOPY 2020; 74:525-535. [PMID: 32167375 DOI: 10.1177/0003702819889374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The application assessment of different programs was performed with equivalence tests for method transfer pro second-order derivative spectrophotometry. The digital second-order derivative spectra were calculated on different instruments; GBC Scientific Equipment Cintra 20 (Cintral v.2.6 and Spectral v.1.70 software programs) and Thermo Scientific Evolution 300 (VISIONPro software) were analyzed using the amplitude A/B ratio (A = 2D265,263; B = 2D263,261). Amplitude A/B ratio is the resolution parameter for derivative spectrophotometry prescribed in European Pharmacopoeia. The obtained values for A/B ratio were either very similar or significantly different among programs: 0.669 (Cintral v.2.6), 0.549 (Spectral v.1.70), 0.556 (medium indirect VISIONPro), 0.557 (one-step Savitzky-Golay 7 VISIONPro), 0.689 (two-step Savitzky-Golay 7 VISIONPro). Method transfer was possible between Spectral v.1.70 and VISIONPro (medium indirect and one-step Savitzky-Golay 7), but the values obtained in Cintral v.2.6 were not comparable to the other programs. The absorbance data exported from both instruments were additionally calculated in OriginPro8 which provided almost the same mean A/B values (0.627 Cintral v.2.6; 0.624 VISIONPro), confirming that the two instruments recorded the same zero-order spectra. The calculation of resolution parameter could be used for verification of program comparison, which would enable transfer between sender and receiver laboratory. The accordance between program algorithms was confirmed when acceptable differences for values of resolution parameter (A/B ratios) were achieved.
Collapse
Affiliation(s)
- Ana Homšek
- Department of Analytical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | - Bojan Marković
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | | | - Sote Vladimirov
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | | |
Collapse
|
4
|
Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates. J Pharm Biomed Anal 2019; 167:7-14. [PMID: 30738243 DOI: 10.1016/j.jpba.2019.01.048] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 01/04/2019] [Accepted: 01/29/2019] [Indexed: 01/09/2023]
Abstract
Budesonide is a potential therapeutic option for the prevention of bronchopulmonary dysplasia in mechanically ventilated premature neonates. The dose and concentrations of budesonide that drive effective prophylaxis are unknown, due in part to the difficulty in obtaining serial blood samples from this fragile population. Of primary concern is the limited total blood volume available for collection for the purposes of a pharmacokinetic study. Dried blood spots (DBS), which require the collection of <200 μL whole blood to fill an entire card, are an attractive low-blood volume alternative to traditional venipuncture sampling. We describe a simple and sensitive method for determining budesonide concentrations in DBS using an ultra-high-performance liquid chromatography - tandem mass spectrometry assay. Budesonide was liberated from a single 6 mm punch using a basified methyl tert-butyl ether extraction procedure. The assay was determined to be accurate and precise in the dynamic range of 1 to 50 ng/mL. The validated assay was then successfully applied to DBS collected as part of a multi-center, dose-escalation study of budesonide administered in surfactant via intra-tracheal instillation to premature neonates between 23 and 28 weeks gestational age. These findings show that DBS are a useful technique for collecting pharmacokinetic samples in premature neonates and other pediatric populations.
Collapse
|
5
|
Validation of a SPE HPLC–UV method for the quantification of a new ER-specific photosensitizer OR-141 in blood serum using total error concept. J Pharm Biomed Anal 2017; 141:87-94. [DOI: 10.1016/j.jpba.2017.03.060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 03/28/2017] [Accepted: 03/29/2017] [Indexed: 11/23/2022]
|
6
|
Gazzotti T, Barbarossa A, Zironi E, Roncada P, Pietra M, Pagliuca G. An LC-MS/MS method for the determination of budesonide and 16α-hydroxyprednisolone in dog plasma. MethodsX 2016; 3:139-43. [PMID: 27408833 PMCID: PMC4929248 DOI: 10.1016/j.mex.2016.02.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 02/22/2016] [Indexed: 11/21/2022] Open
Abstract
Although budesonide is frequently used in veterinary medicine for the treatment of canine respiratory and bowel inflammatory diseases, knowledge is lacking regarding its kinetics in this species. We developed and validated a liquid chromatography–tandem mass spectrometry method for the determination of budesonide and its metabolite 16α-hydroxyprednisolone in dog plasma. The analytes were extracted by solid phase extraction and analysis was performed by high performance liquid chromatography–tandem mass spectrometry, with positive electrospray ionization.This method allows budesonide and one of its main metabolites to be simultaneously quantified in dog plasma at fairly low concentrations. The proposed protocol is very easy and fast to execute, without compromising analytical performances. A small amount (0.5 mL) of plasma is required, making this approach suitable for pharmacokinetic studies also in small sized dogs.
Collapse
Affiliation(s)
- Teresa Gazzotti
- Department of Veterinary Medical Sciences - University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia (BO), Italy
| | - Andrea Barbarossa
- Department of Veterinary Medical Sciences - University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia (BO), Italy
| | - Elisa Zironi
- Department of Veterinary Medical Sciences - University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia (BO), Italy
| | - Paola Roncada
- Department of Veterinary Medical Sciences - University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia (BO), Italy
| | - Marco Pietra
- Department of Veterinary Medical Sciences - University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia (BO), Italy
| | - Giampiero Pagliuca
- Department of Veterinary Medical Sciences - University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia (BO), Italy
| |
Collapse
|
7
|
Phospholipid removal combined with a semi-automated 96-well SPE application for determination of budesonide in human plasma with LC–MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 970:31-5. [DOI: 10.1016/j.jchromb.2014.08.035] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2014] [Revised: 08/26/2014] [Accepted: 08/27/2014] [Indexed: 11/17/2022]
|
8
|
Lu Y, Sun Z, Zhang Y, Chen X, Zhong D. Simultaneous quantification of 22R and 22S epimers of budesonide in human plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry: application in a stereoselective pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 921-922:27-34. [PMID: 23416292 DOI: 10.1016/j.jchromb.2013.01.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2012] [Revised: 01/14/2013] [Accepted: 01/20/2013] [Indexed: 11/18/2022]
Abstract
Budesonide (BUD) is used as a mixture of 22R and 22S epimers for the topical treatment of asthma, rhinitis, and inflammatory bowel disease. To study stereoselectivity in the pharmacokinetics of each epimer, we developed a stereoselective and sensitive ultra-high-performance liquid chromatography-tandem mass spectrometry method for the quantitative determination of 22R and 22S epimers of BUD in human plasma. The epimers of BUD were extracted from plasma using n-hexane/dichloromethane/isopropanol (2:1:0.1, v/v/v) under alkaline conditions. Baseline separation was obtained within 7min on an Acquity UPLC BEH C18 (50mm×2.1mm, 1.7μm) column using an isocratic mobile phase consisting of acetonitrile/5mM ammonium acetate/acetic acid (29:71:0.142, v/v/v) at a flow rate of 0.7mL/min. Mass spectrometric detection was performed in a multiple reaction monitoring mode using the m/z 489→357 transition for BUD epimers and the m/z 497→357 transition for the internal standard d8-BUD epimers. Calibration curves were linear over the concentration ranges of 5.0-500 and 5.0-3000pg/mL for 22R-BUD and 22S-BUD, respectively. The lower limit of quantification was 5.0pg/mL for both epimers. The method was successfully applied in a pharmacokinetic study of BUD controlled-release capsules in humans. Consistent differences in the pharmacokinetics of the 22R and 22S epimers were observed, the AUC(0-∞) of 22S-BUD was approximately six times higher than that of 22R-BUD, and the 22S-/22R-BUD ratio of total body clearance was 0.17.
Collapse
Affiliation(s)
- Youming Lu
- Zhejiang University of Technology, Hangzhou 310014, PR China
| | | | | | | | | |
Collapse
|
9
|
Bouabidi A, Talbi M, Bourichi H, Bouklouze A, El Karbane M, Boulanger B, Brik Y, Hubert P, Rozet E. Flexibility and applicability of β-expectation tolerance interval approach to assess the fitness of purpose of pharmaceutical analytical methods. Drug Test Anal 2012; 4:1014-27. [PMID: 22615163 DOI: 10.1002/dta.1345] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2011] [Revised: 02/06/2012] [Accepted: 02/27/2012] [Indexed: 11/10/2022]
Abstract
An innovative versatile strategy using Total Error has been proposed to decide about the method's validity that controls the risk of accepting an unsuitable assay together with the ability to predict the reliability of future results. This strategy is based on the simultaneous combination of systematic (bias) and random (imprecision) error of analytical methods. Using validation standards, both types of error are combined through the use of a prediction interval or β-expectation tolerance interval. Finally, an accuracy profile is built by connecting, on one hand all the upper tolerance limits, and on the other hand all the lower tolerance limits. This profile combined with pre-specified acceptance limits allows the evaluation of the validity of any quantitative analytical method and thus their fitness for their intended purpose. In this work, the approach of accuracy profile was evaluated on several types of analytical methods encountered in the pharmaceutical industrial field and also covering different pharmaceutical matrices. The four studied examples depicted the flexibility and applicability of this approach for different matrices ranging from tablets to syrups, different techniques such as liquid chromatography, or UV spectrophotometry, and for different categories of assays commonly encountered in the pharmaceutical industry i.e. content assays, dissolution assays, and quantitative impurity assays. The accuracy profile approach assesses the fitness of purpose of these methods for their future routine application. It also allows the selection of the most suitable calibration curve, the adequate evaluation of a potential matrix effect and propose efficient solution and the correct definition of the limits of quantification of the studied analytical procedures.
Collapse
Affiliation(s)
- A Bouabidi
- Analytical Chemistry Laboratory, CIRM, Institute of Pharmacy, University of Liège, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Liquid chromatography tandem mass spectrometry determination of total budesonide levels in dog plasma after inhalation exposure. Anal Bioanal Chem 2011; 402:1209-15. [DOI: 10.1007/s00216-011-5549-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2011] [Revised: 10/26/2011] [Accepted: 11/01/2011] [Indexed: 11/27/2022]
|